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A new, simplified technique for the synthesis of polyethylene glycol (PEG) derivatives of 
proteins utilizing l.l’-carbonyldiimidazole for PEG activation, is described. PEG derivatives of 
superoxide dismutase, cw,-macroglobulin. ol,-macroglobulin-trypsin, and lactoferrin were pre- 
pared and studied. Superoxide dismutase coupled to PEG preserved 95% of its original activity 
while its plasma half-life increased from 3.5 min to 9 or more hours depending on the PEG 
derivative studied. PEG-derivatized cYz-macroglobulin showed decreased protease binding activity 
but PEG derivatives of preformed az-macroglobulin-trypsin demonstrated no loss of activity. 
The plasma clearance of PEG-oc*-macroglobulin-trypsin was prolonged significantly compared 
to native c*2-macroglobulin-trypsin, particularly when a high-molecular-weight PEG was coupled 
to the protease inhibitor complex. The plasma clearance half-life of lactoferrin was increased 5- 
to 20-fold by this modification. Trinitrobenzenesulfonic acid titration studies demonstrated that 
c-amino groups of lysine residues are modified by the coupling of carbonyldiimidazole-activated 
PEG to proteins. 
KEY WORDS: polyethylene glycol-modified proteins: superoxide dismutase; lactoferrin; 01?- 
macroglobulin. 
The hydroxyl groups of monomethoxy- 
polyethylene glycols (HO(-CH2-CH2-0-), 
CH3) may be activated by cyanuric chloride 
and several other reagents and then coupled 
to lysine t-amino groups of proteins (l-5). 
Polyethylene glycol-protein adducts demon- 
strate increased blood circulation time and 
decreased antigenicity and immunogenicity 
as compared to the unmodified proteins (1,6- 
12). Derivatized proteins, however, often 
demonstrate a marked loss of activity (8,lO). 
1, I’-Carbonyldiimidazole reacts with the 
hydroxyl groups on agarose to produce a de- 
rivative that reacts with nucleophiles (13). In 
the present manuscript a simple procedure is 
described for activating polyethylene glycol 
with this reagent. Reactions with monofunc- 
’ To whom all correspondence should be addressed. 
tional (PEG-2 and PEG-5),2 bifunctional 
(PEG-4) and tetrafunctional (PEG-20) poly- 
mers containing one, two, and four hydroxyl 
groups, respectively, are compared.3 Polyeth- 
ylene glycols activated with this reagent cou- 
ple to lysine residues as with other activated 
polyethylene glycols. 
* Abbreviations used: PEG, polyethylene glycol; SOD, 
superoxide dismutase; a2M,a,-macroglobulin; BAPNA, 
N”-benzoyl-DL-arginine-p-nitroanilide-HCl; TNBS, 2.4,6- 
trinitrobenzenesulfonic acid. 
3 The monofunctional polyethylene glycols, PEG-2 and 
PEG-5, each have one of their hydroxyl groups replaced 
by a methoxy group. The bifunctional polyethylene gly- 
col. PEG-4, has two free hydroxyl groups. PEG-20, as 
synthesized by the manufacturer has four free hydroxyl 
groups (Sigma Chemical Co.. Technical Services Divi- 
sion). The number designations for PEG species indicate 
the average molecular weight of the product. 
25 0003-2697/83 $3.00 
Coppght CE 1983 by Academic Press. Inc. 
All rights of reprcductmn m any form reserved. 
26 BEAUCHAMP ET AL. 
The proteins derivatized with the activated 
polyethylene glycols include bovine liver cop- 
per-zinc superoxide dismutase, human 
plasma a*-macroglobulin complexed with 
trypsin, and human milk lactoferrin. These 
proteins are representative of three mecha- 
nisms of plasma clearance. Superoxide dis- 
mutase, Mr = 3 1,200, catalyzes the dispro- 
portionation of 0; (14). Clearance from the 
mammalian circulation results from passive 
diffusion of the relatively small protein 
through the renal glomeruli (15). Lactoferrin 
is an iron-binding protein found in the gran- 
ules of neutrophils which may play an im- 
portant role in tissue injury mediated by 
phagocytes ( 16). It is rapidly cleared from the 
circulation by hepatocytes as a result of car- 
bohydrate recognition ( 17). a*-Macroglobu- 
lin is a high-molecular-weight plasma pro- 
tease inhibitor (18). Following reaction with 
a protease, the complex is recognized by re- 
ceptors in the reticuloendothelial system and 
rapid clearance occurs ( 19). The receptor rec- 
ognition site is present on the inhibitor and 
most likely involves a sequence of amino ac- 
ids which either becomes exposed or assumes 
an appropriate conformation after reaction 
with protease. 
The clearance rates of the native and poly- 
ethylene glycol-derivatized forms of these 
proteins are compared in mice. The results of 
in vitro activity experiments are also pre- 
sented. Using published data and these stud- 
ies, a comparison is made of some of the ad- 
vantages and disadvantages of the cyanuric 
chloride and 1, I’-carbonyldiimidazole pro- 
cedures for synthesis and polyethylene glycol- 
protein derivatives. 
MATERIALS AND METHODS 
Materials. Bovine serum albumin, trypsin, 
BAPNA, 1, I’-carbonyldiimidazole, TNBS, p- 
nitrophenyl-p’-guanidinobenzoate-HCl, cy- 
tochrome c type IV and SBTI were obtained 
from Sigma. Trypsin, purchased from Wor- 
thington, was 70% active by active-site titra- 
tion with p-nitrophenyl-p’-guanidinoben- 
zoate-HCl (20). Burdick-Jackson ultrapure 
dioxane was obtained from Anspec, Ann Ar- 
bor, Michigan; lactoperoxidase bound to Se- 
pharose-4B from P-L Biochemicals; ‘25I for 
protein iodination from New England Nu- 
clear; DE-52 from Whatman; electrophoresis 
reagents from Bio-Rad; and ultrapure am- 
monium sulfate from Schwartz/Mann. Spec- 
trapor dialysis tubing was obtained from 
Fisher. PEG-4 (Carbowax 4000) was pur- 
chased from Fisher, PEG-2 and PEG-5 from 
Polyscience, and PEG-20 from Sigma. Lac- 
toferrin prepared according to Querinjean et 
al. (2 1) was generously supplied by Jean-Paul 
Prieels, Universite Libre de Bruxelles. Human 
plasma azM was purified by a modification 
(19) of the method of Kurecki et al. (22). All 
other reagents were the best commercial grade 
available. 
Electrophoresis. Native polyacrylamide gel 
electrophoresis was performed on 5% slabs 
with the continuous Tris-borate system of 
Nelles et al. (23) or on 7.5% gels using the 
discontinuous buffer system of Davis (24). 
Gels were stained with Coomassie brilliant 
blue G-250. 
Enzyme activity assays. SOD activity was 
measured according to the procedure of 
McCord and Fridovich ( 14). The ability of 
a2M to bind trypsin following reaction with 
PEG was studied with a modification of the 
method of Ganrot (28). A detailed description 
of the procedure is presented elsewhere (29). 
In other experiments, azM-trypsin complex 
was preformed and then reacted with acti- 
vated PEG. BAPNA substrate was added and 
amidolytic activity was assayed. 
Protein concentrations. The concentrations 
of unmodified proteins were calculated us- 
ing the following extinction coefficients 
and molecular weight determinations: (YAM, 
@& 280 nm = 8.93, M, = 718,000 (25) lac- 
toferrin, At:,, 28o “,,, = 10, M, = 77,000 (21), 
bovine copper-zinc SOD, A is&,, 28o “,,, = 2.70, 
M, = 3 1,200 (14,26). The concentration of 
PEG-modified protein was estimated by the 
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Biuret procedure (27). The unmodified pro- 
teins served as standards. 
Purljication of bovine liver copper-zinc 
SOD. The procedure of McCord and Fridov- 
ich ( 14) for isolating SOD from bovine eryth- 
rocytes was modified for a bovine liver source. 
All steps were performed at 4°C unless oth- 
erwise specified. Fresh bovine liver (900 g) was 
homogenized in a Waring blender for 2 min 
in 2 liters of deionized water and then filtered 
through cheese cloth. Ethanol (0.25 vol) and 
chloroform (0.15 vol) were added with stirring 
and the mixture centrifuged (9200g) for 30 
min. To the supernatant, 300 g/liter of an- 
hydrous K2HP04 was added with stirring and 
the preparation was centrifuged for 20 min at 
2 1 ,OOOg. The supernatant was placed in a sep- 
aratory funnel and the upper ethanol phase 
was collected and centrifuged for 20 min at 
2 1 ,OOOg. The supernatant was again placed in 
a separatory funnel to remove and discard 
residual lower phase. The upper ethanol phase 
containing SOD activity was rapidly cooled 
to between -2 and -5°C in a salt-ice bath 
and 0.75 vol of acetone at -20°C were added 
with stirring. The mixture was immediately 
centrifuged (2 1 ,OOOg) for 20 min and the pre- 
cipitate collected and dispersed with a Ten- 
broek homogenizer in 100 cm3 cold deionized 
H20. Ammonium sulfate (32.6 g/l00 ml) was 
added, the mixture centrifuged (2 1 ,OOOg) for 
20 min, and the precipitate discarded. The 
supernatant was dialyzed against 2.5 mM KP,, 
pH 7.45 and applied to a DE-52 column (2.5 
X 35 cm) equilibrated in the same buffer at 
4°C. The column was eluted sequentially at 
pH 7.45 with 250 ml each of 2.5 mM Kp,, 
and 10 mM KI’i with 7 ml fractions collected 
at 2 ml/min. SOD eluted from the column at 
the 10 mM KP; step. Purity of the fractions 
was determined by polyacrylamide gel elec- 
trophoresis. Fractions containing pure SOD 
were pooled. Fractions containing significant 
amounts of impure SOD were pooled and re- 
chromatographed on the same DE-52 col- 
umn. The presence of two to three SOD iso- 
enzymes was verified by comparison of gels 
stained for protein with gels stained for SOD 
activity (30). The purified SOD had a specific 
activity of 3200 units/mg using the activity 
assay of McCord and Fridovich (14) and a 
protein determination as described by Mur- 
phy and Kies (31). 
Radioiodination of proteins. Proteins were 
radiolabeled by the solid state lactoperoxidase 
procedure of David and Reisfeld (32). The 
specific activities in cpm/pg of the proteins 
were SOD, 1.3 X 104; lactoferrin, 5.7 X 104; 
and CY~M, 5.5 X 105. 
Activation of PEG. The PEG was dissolved 
in dioxane at 37°C at a concentration of 50 
mM (PEG-2, PEG-4, and PEG-5) or 5 mM 
(PEG-20) and 1 , 1’-carbonyldiimidazole added 
to a final concentration of 500 mM. The so- 
lution was incubated at 37°C for 2 h with stir- 
ring and then dialyzed extensively against Hz0 
at 4°C. The activated PEG-2, PEG-4, and 
PEG-5 solutions were dialyzed in Spectrapor 
dialysis membranes with 1000,2000, and 3500 
M, inclusion limits, respectively, and the ac- 
tivated PEG-20 solution was dialyzed in a di- 
alysis membrane with a 10,000 A4, inclusion 
limit. The solutions were then lyopholized and 
stored dessicated at 4°C. The resultant pow- 
der constituted “activated PEG.” 
Elemental analysis of activated PEG deriv- 
atives. Analysis for percent hydrogen, carbon, 
oxygen, and nitrogen content of the activated 
PEG derivatives was performed by Spang Mi- 
croanalytical Laboratory (Eagle Harbor, 
Mich.). 
TNBS titration studies. The percentage of 
SOD amino groups that reacted with the ac- 
tivated PEG was determined using the TNBS 
titration procedure described by Glazer et al. 
(33). Prior to the TNBS titration, the PEG- 
SOD adducts were dialyzed in tubing with a 
50,000 A4, cutoffand concentrated in an Ami- 
con ultrafiltration apparatus with an XM-50 
membrane. 
Coupling of activated PEG to proteins. Ac- 
tivated PEG-4 and 5 (90 mM) and radiola- 
beled SOD (5 X lO-5 M) were incubated in 10 
mM sodium borate, pH 8.5, and 4°C for 48 
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FIG. I. Proposed mechanism for the formation of l,l’- 
carbonyldiimidazole-activated monofunctional PEG and 
for the reaction of the activated PEG with amino groups 
of a protein. 
h. At 48 h, the concentration of activated PEG- 
5 was increased to 180 tnM and the incuba- 
tion continued for another 48 h. In other 
studies, 180 mM PEG-5 was present for the 
entire 96-h incubation. 
Trypsin was incubated with radiolabeled 
azM in 10 IIIM sodium borate, pH 8.5, for 5 
min at room temperature at a trypsin to pro- 
tease inhibitor ratio of 2. Activated PEG-2, 
PEG-4, and PEG-5 (40 mM) were incubated 
with 1 X 10e6 M azM-trypsin complex in the 
same buffer for 72 h. Activated PEG-20 (10 
mM) was incubated with 5 X lo-’ M azM- 
trypsin complex for 72 h. Uncomplexed azM 
was reacted with PEG under similar condi- 
tions. 
Activated PEG-2 or 4 (40 or 160 mM) and 
radiolabeled lactofetrin (4 X 10e6 M) were in- 
cubated in 10 mM sodium borate, pH 8.5, at 
4 C” for 72 h. 
Clearance studies. Clearance studies were 
performed in 20-week-old CD- 1 female white 
mice as previously described (19,34). Studies 
were generally performed in triplicate and the 
results averaged. Each individual study varied 
by less than 5% compared to the mean. 
RESULTS 
Elemental analysis of activated PEG deriv- 
atives. The expected product of the reaction 
of 1 , 1’-carbonyldiimidazole with the hydroxyl 
group of PEG is an imidazole carbamate de- 
rivative ( 13). Figure 1 illustrates the proposed 
structure of activated PEG formed by this 
procedure. The nitrogen content for each of 
the activated PEG derivatives was calculated 
using this general structure, and the predicted 
value compared to the actual content deter- 
mined by elemental analysis of the activated 
PEG derivatives (Table 1). For each of the 
activated PEG derivatives, experimental ni- 
trogen content was essentially identical to the 
calculated percent nitrogen from the structure 
of activated PEG in Fig. 1. 
TNBS titration of the PEG derivatives of 
SOD. TNBS titration was performed to de- 
termine if amino groups of the PEG-deriva- 
tized protein were modified as predicted by 
the structure of the PEG-protein adduct given 
in Fig. 1. The PEG-4 and PEG-5 derivatives 
of SOD were extensively dialyzed in 50,000 
M, inclusion limits dialysis tubing and con- 
centrated using a filtration membrane with a 
similar cutoff to remove PEG which interferes 
with TNBS titration (data not shown). The 
TNBS titration results showed the PEG-4 de- 
rivative of SOD had 5% and the PEG-5 de- 
rivative 10% titratable amino groups as com- 
pared to the unmodified protein. 
Gel electrophoresis of PEG modified SOD. 
Polyacrylamide gel electrophoresis was used 
to demonstrate that incubation of activated 
PEG with SOD produces an altered form of 
the enzyme and to study the effect of different 
incubation conditions on the formation of a 








PEG-2 1.3 1.1 
PEG-4 1.6 1.6 
PEG-S 0.55 0.44 
PEG-20 0.56 0.56 
Note. The % nitrogen found is compared to the % ni- 
trogen predicted from the structures of activated PEG 
shown in Fig. 1. 
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concentrations of activated PEG-5 on SOD 
derivitization is shown in Fig. 2. The nature 
of the PEG-protein adduct varies with the 
reaction conditions. Altered electrophoretic 
behavior probably reflects both decreased 
positive charge and increased size of the mod- 
ified protein. The greater mobility electro- 
phoretic bands in gels B, C, and D of Fig. 2 
should represent unmodified and less highly 
modified protein. 
Activity and clearance of PEG-mod$ed 
SOD. The catalytic activity of SOD after 
modification with PEG-4 and PEG-5 was de- 
A B C D 
FIG. 2. Polyacrylamide gel electrophoresis under native 
conditions (24) of SOD and its PEG-5 derivative. Twenty 
micrograms of protein was applied to each gel lane. Gel 
A-unmodified SOD; gel B-SOD incubated with 90 mM 
activated PEG-5 for 48 h; gel C-SOD incubated with 90 
mM activated PEG-5 for 48 h at which time the concen- 
tration of PEG-5 was doubled and the incubation con- 
tinued for another 48 h; gel D-SOD incubated with 180 
mM activated PEG-5 for 96 h. The direction of migration 
is from top to bottom with bottom being the anode. 
IO A d 
12 24 36 48 
Time (hr) 
FIG. 3. Blood clearance in the mouse of SOD and its 
PEG derivatives. Graph shows the clearance of unmo- 
dified (0) PEG-5 (m), and the PEG-4-derivatized SOD 
(0). 
termined. For both of these derivatives the 
enzyme retained greater than 95% of its ac- 
tivity. This compares to only 5 1% retention 
of enzymatic activity upon derivatization of 
SOD with cyanuric chloride activated PEG 
(8). The clearance of intravenously injected 
SOD and its PEG-4 and PEG-5 derivatives 
are shown in Fig. 3. Less than 15% of the 
native protein remained in the circulation 20 
min after injection whereas approximately 
20% of the PEG-5 derivative and 30% of the 
PEG-4 derivative remained in the circulation 
40 h after injection. The apparent half-life of 
SOD was 3.5 min for the native protein, 9 h 
for the PEG-5 derivative, and 16.5 h for the 
PEG-4 derivative. 
Activity of PEG-modified azA4 and (~&f- 
trypsin complex. The PEG-2, PEG-4, PEG-5, 
and PEG-20 derivatives of azM demonstrated 
trypsin binding activities of 80, 35, 38, and 
63%, respectively, as compared to the un- 
modified protein. This decrease in trypsin 
binding activity may result from steric hin- 
drance in the interaction of the PEG-modified 
LYZM with trypsin. There was, however, an in- 
crease in qM-trypsin amidolytic activity for 
each of the PEG derivatives of preformed 
azM-trypsin complex. For the PEG-2, PEG- 
4, PEG-5, and PEG-20 derivatives of azM- 
trypsin complex the amidolytic activity was 
120, 120, 102, and 270%, respectively, of the 
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FIG., 4. Native polyacrylamide gel electrophoresis per- 
formed on 5% slabs according to Nelles et al. (23) of +M- 
trypsin complex and its PEG derivatives. Five to seven 
micrograms of each protein sample was applied. Gel A- 
unmodified ozM-trypsin complex; gel B-PEG-2 deriv- 
ative; gel C-PEG-4 derivative; gel D-PEG-20 deriva- 
tive. The direction of migration is from top to bottom 
with the bottom being the anode. 
control value. In control experiments, un- 
reacted PEG had no effect on the activity of 
a*M-trypsin when added simultaneously with 
the substrate BAPNA. Trypsin amidolytic ac- 
tivity is increased after PEG derivatization us- 
ing the cyanuric chloride procedure (35). The 
present results may represent a similar phe- 
nomenon. 
Electrophoresis of PEG-modijied (YAM- 
trypsin complex. Figure 4 shows a comparison 
between the electrophoretic mobilities in a 
native electrophoresis system of unmodified 
and PEG-modified crzM-trypsin complex. The 
PEG derivatives of qM-trypsin complex dis- 
tributed in a broader band than unmodified 
azM-trypsin suggesting some heterogeneity 
in the population of derivatives. The de- 
20 40 60 80 100 120 140 16( 
Trne (mln) 
1 
FIG. 5. Clearance of ozM-trypsin complex, and its PEG 
derivatives. The graph shows the clearance of unmodified 
a,M-trypsin complex (0), PEG-2 (O), PEG-4 (m), PEG- 
5 (IX), and PEG-20-derivatized crzM-T (A). Native arzM 
(A) is shown for comparison. 
creased mobilities of the derivatives most likely 
reflect decreased positive change and in- 
creased size as was the case for SOD. 
Clearance of PEG-modified a2A4-trypsin 
complex. Figure 5 shows the clearance of qM- 
trypsin complex before and after reaction with 
activated PEG. The clearance of unmodified 
cu2M-trypsin complex was rapid in agreement 
with previous studies (19,34). The PEG de- 
rivatives of azM-trypsin complex cleared at 
a decreased rate. Reactions with higher mo- 
lecular weight PEGS resulted in a more pro- 
nounced inhibition of clearance. The appar- 
ent half-life of the PEG-20 derivative ap- 
proached that of the unreacted inhibitor. 
Clearance of PEG-modified lactoferrin. Fig- 
ure 6 shows the clearance of native and PEG- 
IO' 
20 40 60 80 100 120 
Time (min) 
FIG. 6. Clearance of native and PEG modified lacto- 
ferrin. The graph shows clearances of unmodified (0), 
PEG-2 (A), and PEG-4 derivatives of lactoferrin (m). 
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modified lactoferrin. The half-life increased 
from less than 3 min for unmodified lacto- 
ferrin to 15 min for the PEG-Zmodified pro- 
tein and to 60 min for the PEG-4 derivative. 
Unlabeled native lactoferrin significantly 
competed for clearance with the PEG-2 de- 
rivative of radiolabeled lactoferrin. When a 
3000-fold molar excess of unlabeled native 
lactoferrin was injected with the radiolabeled 
derivative, the clearance of the derivative was 
prolonged fivefold. This result suggests that 
the derivatized protein clears on the same he- 
patocyte receptor that clears native lactoferrin 
(17). Lactoferrin precipitated when incubated 
with 40 mM PEG-5 or greater than 160 mM 
PEG-2 or PEG-4. Electrophoresis confirmed 
that the precipitates contained lactoferrin. 
Precipitated lactoferrin when redissolved 
cleared at a rate typical of the unmodified 
protein suggesting that no derivatization oc- 
curred. PEG is capable of precipitating many 
proteins without denaturation (36) and it ap- 
pears likely that this phenomenon was ob- 
served under these reaction conditions. 
DISCUSSION 
Proteins are increasingly important in clin- 
ical medicine as drugs, but many of these pro- 
teins must be obtained from nonhuman 
sources since insufficient amounts can be pu- 
rified from available human tissue or, for ex- 
ample, as in the case of streptokinase, the pro- 
tein is not synthesized by eukaryotic organ- 
isms (see Ref. (34) for a discussion of the uses 
of streptokinase). This raises the problem of 
protein antigenicity. A second problem en- 
countered when proteins are used as drugs is 
the short half-lives of many of these prepa- 
rations. As an example, streptokinase has a 
half-life of only about 15 min (34). 
Two interesting characteristics of some 
PEG-protein adducts, as compared to the un- 
modified proteins, are an increase in blood 
circulation time and a decrease in antigenicity 
and immunogenicity ( 1,6). Unfortunately, the 
coupling of PEG to proteins often results in 
substantial loss of activity. The coupling of 
cyanuric chloride activated PEG to SOD re- 
sults in an approximate loss of 50% of the 
activity. Modification of L-glutaminase-L-as- 
paraginase results in loss of almost 90% of its 
activity (6,lO). 
This report describes a new technique for 
linking PEG polymers to proteins by using an 
easily prepared carbonyldiimidazole-acti- 
vated PEG. The formation and isolation of 
the activated PEG is a simple three-step pro- 
cedure consisting of incubating carbonyldi- 
imidazole with PEG in a nonaqueous solvent, 
dialyzing the product against water, and ly- 
ophilizing the preparation. The resultant “ac- 
tivated PEG” is an imidazole carbamate de- 
rivative of the hydroxyl group of the polymer 
as illustrated in Fig. 1 for a monofunctional 
PEG. Support for this proposed structure was 
obtained by elemental analysis. 
The proteins derivatized with the activated 
polyethylene glycols were chosen to represent 
three different mechanisms of plasma clear- 
ance; namely, passive excretion (SOD), rec- 
ognition of unique amino acid recognition 
sites by a receptor (azM-trypsin), and car- 
bohydrate recognition by receptors (lactofer- 
tin) (15,17,19). Two of these proteins have 
the additional advantage of possessing an en- 
zyme activity (SOD) and a protease binding 
function (cQM), which can be evaluated after 
PEG modification. The antigenicity or im- 
munogenicity of PEG adducts prepared by 
use of carbonyldiimidazole-activated PEG was 
not evaluated. These properties are not pre- 
dictable a priori and must be evaluated for 
each PEG-protein adduct prepared by any of 
the reported coupling procedures. 
When SOD was incubated with a 3600-fold 
molar excess of activated PEG-4 or PEG-5, 
less than 10% of the free amino groups re- 
mained. This compares favorably with cy- 
anuric chloride-activated PEG-5 derivatiza- 
tion of SOD (8). The PEG-4 adduct of SOD 
made with carbonyldiimidazole-activated 
PEG had greater than 95% of the activity of 
native SOD and a blood circulation half-life 
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of 16 h. The PEG adduct of SOD made with 
cyanuric chloride-activated PEG had a simi- 
lar half-life, but as described above, retained 
only 5 1% catalytic activity (8). 
There was also a striking change in the blood 
circulation half-life of lactoferrin after deri- 
vatization with carbonyldiimadazole acti- 
vated PEG. Native lactoferrin competed for 
the clearance of a radiolabeled PEG-lacto- 
ferrin complex consistent with the clearance 
of the modified derivative by the same mech- 
anism which clears the native protein, albeit 
at a slower rate. 
The ability of PEG-modified LY~M to bind 
trypsin was decreased significantly, presum- 
ably because of steric hindrance in the inter- 
action of the PEG modified qM with trypsin. 
PEG modification of preformed azM-tryp- 
sin, however, yielded derivatives which did 
not demonstrate loss of amidolytic activity. 
Clearance studies of cyzM-trypsin demon- 
strated that a relatively large polymer (PEG- 
20) was necessary to cause an increase in the 
plasma half-life in contrast with the PEG de- 
rivatives of SOD and lactoferrin. The plasma 
clearance of PEG-20-azM-trypsin actually 
approached that of the native molecule. 
The plasma clearances of the PEG adducts 
of SOD, lactoferrin, and azM-trypsin were 
generally biphasic while the clearances of the 
native ligands were essentially first order. This 
difference probably reflects some heteroge- 
neity in the extent of protein modification. 
The comparisons, therefore, of the half-lives 
of modified and unmodified proteins is some- 
what misleading since it tends to underesti- 
mate the actual increase in the circulating half- 
lives of the modified proteins. This was par- 
ticularly evident for the PEG derivatives of 
lactoferrin where the apparent half-life in- 
creased from about 3 min for the reactive 
molecule to 15 min (PEG-2) and 60 min 
(PEG-4) respectively. In each case, 50 to 75% 
of the modified protein population actually 
demonstrated a plasma clearance of several 
hours. 
These studies document the utility of car- 
bonyldiimidazole-activated PEG as a cou- 
pling reagent for proteins. This procedure of- 
fers a simplified approach for preparing such 
derivatives. The method may be particularly 
useful where other such procedures result in 
protein inactivation. 
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